A new Medicare program launched July 1, 2026, allowing some Medicare beneficiaries to obtain certain GLP-1 medications for $50 a month. But eligibility is not automatic. Here’s what Medicare beneficiaries need to know about the Medicare GLP-1 Bridge.
For years, Medicare beneficiaries have faced significant barriers when trying to get GLP-1 medications for weight management.
That changed on July 1, 2026, when the Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge, a temporary program providing eligible Medicare beneficiaries access to certain GLP-1 medications for $50 per month.
The program currently includes Foundayo, Wegovy and Zepbound, but there are important eligibility requirements. The program is scheduled to continue through December 31, 2027. CMS says the program is available nationwide.
So who qualifies—and how does the $50 price actually work?
What is the Medicare GLP-1 Bridge?
The Medicare GLP-1 Bridge is a temporary CMS demonstration program designed to provide certain Medicare Part D beneficiaries access to GLP-1 medications specifically for weight management.
Under the program, eligible beneficiaries pay $50 for a monthly supply. The $50 copay is outside the normal Medicare Part D payment system.
That means the $50 payment:
- Does not apply to the Part D deductible.
- Does not count toward the Part D annual out-of-pocket limit.
- Does not count toward a beneficiary’s Part D true out-of-pocket spending.
- Is not reduced by the Part D Low-Income Subsidy or Extra Help.
CMS says the program has been extended through the end of 2027. The official CMS Medicare GLP-1 Bridge information explains the program and its requirements.
Which GLP-1 drugs are included?
As of 2026, the Medicare GLP-1 Bridge covers three products when prescribed for the program’s weight-management indication:
| Medication | Included in GLP-1 Bridge? | Important detail |
|---|---|---|
| Wegovy | Yes | Injection and tablet formulations |
| Zepbound | Yes | KwikPen formulation only |
| Foundayo | Yes | Tablet |
| Ozempic | No | Not included in the Bridge |
| Mounjaro | No | Not included in the Bridge |
The Zepbound limitation is particularly important. CMS says the single-dose Zepbound pens and vials are not includedin the Bridge program.
Foundayo is also a legitimate FDA-approved medication, not an unfamiliar or unapproved product. The FDA approved Foundayo (orforglipron) in April 2026 for adults with obesity, or adults with overweight who have at least one weight-related medical condition, when used with diet and physical activity.
Who qualifies for the $50 Medicare GLP-1 Bridge?
Not everyone with Medicare qualifies.
Generally, a person must be at least 18, have eligible Medicare Part D coverage, meet specific clinical criteria, and be seeking the medication for weight management.
The clinical criteria include one of the following:
BMI of 35 or higher
An adult with a BMI of 35 or higher may qualify for the Bridge when the medication is prescribed to reduce excess body weight and maintain weight reduction.
BMI of 30 or higher plus certain conditions
A person with a BMI of 30 or higher may qualify if they also have one of the following:
- Heart failure with preserved ejection fraction (HFpEF)
- Uncontrolled hypertension despite treatment with two blood-pressure medications
- Chronic kidney disease stage 3a or higher
BMI of 27 or higher plus certain conditions
A person with a BMI of 27 or higher may qualify if they have one of the following:
- Prediabetes
- A previous heart attack
- A previous stroke
- Symptomatic peripheral artery disease
The prescribing clinician must submit the required prior authorization information and attest that the patient meets the program requirements.
CMS provides the detailed clinical eligibility criteria for providers and pharmacies.
Having Medicare Part D is not enough
One of the biggest misconceptions is that simply having Medicare Part D automatically makes someone eligible for the $50 GLP-1 Bridge.
It does not.
The program is available to people with certain types of Medicare drug coverage, including:
- Stand-alone Medicare Prescription Drug Plans (PDPs)
- Medicare Advantage plans that include prescription drug coverage (MA-PD)
Some Medicare plan types are excluded.
CMS also has an important rule for people who have already obtained a GLP-1 through their Medicare drug plan.
If a beneficiary received a GLP-1 medication through Part D during 2026, that person is generally not eligible for the Medicare GLP-1 Bridge in 2026 and should continue receiving the medication through the existing Part D coverage.
What if Medicare already covers the GLP-1?
This is where the distinction between weight management and another medical indication becomes important.
The Medicare GLP-1 Bridge is intended primarily for people seeking these medications for weight management.
Some GLP-1 medications may be covered through Medicare Part D when used for other medically accepted indications.
For example, Wegovy has an FDA-approved indication to reduce the risk of cardiovascular death, heart attack and stroke in certain adults with established cardiovascular disease and overweight or obesity.
Zepbound is FDA-approved for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity.
These types of prescriptions may be handled through the beneficiary’s regular Part D coverage rather than the $50 Bridge.
CMS specifically says that beneficiaries using GLP-1 medications for Part D-covered indications should continue to obtain them through their Medicare drug plan.
What about diabetes?
The Medicare GLP-1 Bridge is not intended to replace Part D coverage for people using GLP-1 medications to treat type 2 diabetes.
CMS says people with type 2 diabetes should pursue coverage through their Medicare Part D plan.
The same basic principle applies to certain other Part D-covered indications, including moderate-to-severe obstructive sleep apnea and certain forms of metabolic dysfunction-associated steatohepatitis (MASH).
In other words, the question is not simply:
“Do I qualify for a GLP-1?”
It is:
“What medical condition is the medication being prescribed to treat, and which Medicare coverage pathway applies?”
Is the $50 really $50?
For someone who qualifies for the Medicare GLP-1 Bridge, yes—the program’s copay is $50 per month.
But there is an important catch: the $50 payment does not count toward the Medicare Part D deductible or annual out-of-pocket spending.
That is different from a normal Part D prescription.
For example, if someone pays $50 per month through the Bridge, those payments are not accumulating toward the Part D out-of-pocket limit.
The Bridge’s $50 copay also is not reduced by Extra Help.
Medicare’s Prescription Payment Plan also does not apply to the $50 Bridge copay because the medication is being provided outside the Part D benefit.
Medicare GLP-1 Bridge vs. regular Part D coverage
| Feature | Medicare GLP-1 Bridge | Regular Part D |
|---|---|---|
| Purpose | Primarily weight management | Covered Medicare indications |
| Monthly cost | $50 for eligible beneficiaries | Depends on plan and drug |
| Part D deductible | Does not apply | May apply |
| Counts toward Part D out-of-pocket limit | No | Generally yes for covered Part D spending |
| Prior authorization | Yes | Often required |
| Extra Help | Does not reduce Bridge copay | Can reduce eligible Part D costs |
| Program period | July 1, 2026–Dec. 31, 2027 | Ongoing Medicare benefit |
What should you do if you think you qualify?
Start with your doctor and pharmacy, not a social-media advertisement or a third-party weight-loss website.
Step 1: Confirm your Medicare coverage
Make sure you have an eligible Medicare Part D plan or Medicare Advantage plan with prescription drug coverage.
Step 2: Check your BMI and medical history
Ask your clinician whether you meet the Bridge’s BMI and medical-condition requirements.
Step 3: Ask which medication is appropriate
The Bridge includes Foundayo, Wegovy and Zepbound, but not every formulation of every drug.
Step 4: Have your provider submit the required authorization
Your clinician must provide the information needed for the Bridge’s prior authorization process.
Step 5: Ask the pharmacy to process the prescription correctly
If the prescription qualifies, the pharmacy should process it through the Medicare GLP-1 Bridge rather than treating it as an ordinary cash prescription or a commercial manufacturer coupon.
What if you don’t qualify?
Not qualifying for the Bridge does not necessarily mean you have no options.
A GLP-1 may potentially be covered under your existing Medicare Part D plan if it is prescribed for a Medicare-covered indication.
You can also ask about:
- Your plan’s formulary
- Prior authorization requirements
- Formulary exceptions
- Mail-order pharmacy pricing
- State prescription assistance programs
- Medicare Extra Help, if eligible
- Other legitimate manufacturer assistance programs
Medicare’s Extra Help program can reduce Part D prescription costs for people who meet its income and resource requirements.
Be careful with online $50 GLP-1 offers
The new Medicare GLP-1 Bridge makes a legitimate $50 monthly price available to qualifying beneficiaries. But that does not mean every “$50 GLP-1” advertisement is connected to Medicare.
Before paying a telehealth company, membership service or online pharmacy, ask:
- Is this the official Medicare GLP-1 Bridge?
- Is the medication actually Foundayo, Wegovy or the eligible Zepbound formulation?
- Is the pharmacy licensed?
- Is the $50 price the medication cost or does it exclude membership, consultation, laboratory or shipping fees?
- Does Medicare eligibility affect the offer?
- Will the prescription be processed through the Medicare GLP-1 Bridge or purchased as a cash prescription?
Be especially cautious about offers involving compounded medications or products that do not clearly identify the FDA-approved drug being dispensed.
The bottom line
The Medicare GLP-1 Bridge is real—and the $50 monthly price is real for eligible Medicare beneficiaries.
Starting July 1, 2026, eligible beneficiaries can obtain certain formulations of Wegovy, Zepbound and Foundayo for $50 per month through the temporary CMS program, which is currently scheduled to continue through December 31, 2027.
But eligibility depends on more than simply having Medicare.
Your Medicare drug coverage, BMI, medical history, the reason the drug is being prescribed, prior GLP-1 use and the medication/formulation all matter.
Before assuming you qualify, check the official Medicare rules and have your doctor and pharmacy verify the appropriate coverage pathway.
For the most current eligibility information, visit Medicare.gov or CMS.gov rather than relying on an advertisement or social-media post.
Thank you, You will be automatically subscribed to the our newsletter.